To treat or not to treat the" immunotolerant phase" of hepatitis B infection: A tunnel of controversy

Mohamed A Mekky

Abstract:

Hepatitis B virus (HBV) infection is a global public health problem, with an estimated 350 million people worldwide chronically infected and approximately 500000 who die annually from HBV-related liver diseases. Management of chronic HBV is challenging and waves of guidelines emerge every year. One of the hottest topics and a matter of debate is the management of patients in their early immunotolerant phase of infection. With the lack of evidence, dealing with this particular subset of patients creates a great conflict with opposing views. In this review, the author highlights the pros and cons of these views and proposes a reasonable solution to resolve this dilemma.

Keywords:

Keywords: Liver biopsy, Hepatitis B Virus, Immunotolerant phase, Polymerase chain reaction, Nucleotide analogue

Published In:

World journal of hepatology , ,